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Abstract  Very recently, we proposed an ordinary differential equation model incorporating 
promotion of regulatory T cell (Tregs) expansion by leukemic cells, which describes co-evolutional 
dynamics between leukemic and immune cells in progression of acute myeloid leukemia (AML). 
To evaluate the ability of our model to predict effectiveness of immunotherapy for AML, we 
performed Monte Carlo simulation of trajectories in phase plane and generated relapse free survival 
(RFS) curves, which could be compared with clinical data. The resulting RFS curves were in good 
accordance with clinical outcomes reported in immunotherapies of NK cells infusion with/without 
Tregs depletion. In addition, our simulation results focusing on consecutive cycles of cell infusion 
with/without cell depletion qualitatively accounts for the effectiveness of corresponding clinical 
immunotherapy. The present results suggest that our model may provide valuable information for 
future design of immunotherapy in AML. 
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1  Introduction 
 
Although the vast majority of patients with newly diagnosed acute myeloid leukemia (AML) achieve 
cytological complete remission (CR) with induction chemotherapy, they have poor prognosis with 
an overall 5-year survival rate of approximately 27 % due to relapse, despite following consolidation 
therapy. While cell survival leading to AML relapse is associated with clonal heterogeneity already 
existing at diagnosis [1], there is accumulating evidence that immunosuppressive AML 
microenvironments developing through interaction of immune cells with leukemic cells contribute 
to disease progression and relapse.  
AML antigen-specific cytotoxic T lymphocytes (CTLs) are detected in both peripheral blood and 
bone marrow of patients and have the capacity to kill leukemic cells. Conversely, over expression 
of immunosuppressive molecules in leukemic cells leads to CTL inhibition, proliferation of 
leukemic cells and leukemia progression through multiple mechanisms. Regulatory T cells (Tregs) 
defined by transcription factor FoxP3 expression play a key role in such immunosuppressive 
mechanisms. While Tregs physiologically play critical roles in the immune tolerance to suppress 
       Modeling immunotherapy and outcomes in acute myeloid leukemia 26  
excessive responses in allergy or autoimmunity[2,3], Tregs have an increased frequency in patients 
with AML[4] and suppress the effector T cells (Teffs) including natural killer (NK) cells and CTLs. 
The expressions of PD-L1, a ligand for programmed death-1 (PD-1) receptor, indoleamine 2,3-
dioxygenase(IDO) and CD200, a type-1 transmembrane glycoprotein in leukemic cells promote 
formation of Tregs[5-8]. An increased frequency of Tregs induced by such immunosuppressive 
molecules results in CTLs suppression and immune evasion. 
Allogeneic hematopoietic stem cell transplantation (alloHSCT) as post-remission therapy is still 
a promising treatment option to prevent relapsing leukemia, in which donor T cells is expected to 
eliminate residual leukemia cells. While the curative efficacy of HSCT logically has led to the 
infusion of manipulated T cells to have enhanced anti-leukemic cytotoxic ability, or the activation 
of endogeneous T cells by supportive cytokine therapy for patients without suitable donors, there 
has been considerable interest in targeting Tregs mediated-suppression of anti-AML reactive T cells. 
In a rodent model with advanced AML, the efficacy of adoptive CTL therapy was improved by 
preceding depletion of endogeneous Tregs using IL-2 diphtheria toxin (IL-2DT) [9]. Tregs depletion 
by IL-2DT improves CR rates and disease-free survival of patients with relapsed or refractory AML 
receiving NK cells infusion[10]. A phase 1 study of Tregs-depleted donor lymphocyte infusion for 
patients with relapsed AML showed promising results of improved outcomes[11]. 
Our aim is to construct a mechanistic mathematical model for leukemia dynamics under the 
impact of developing immunosuppressive environment, which contributes to design protocols of 
immunotherapy for leukemia. Very recently, we proposed an ordinary differential equation model to 
describe the dynamics of three components in AML: leukemic blast cells(L), matured Tregs (Treg) 
and matured effective T cells (Teff) including NK cells and CTLs, in which L promotes Treg 
expansion[12]. Several mathematical modeling have focused on the interaction of immune cells with 
leukemic cells[13-15]. These models incorporated the leukemic cell expansion, the promotion of 
cytotoxic immune cell expansion by leukemic cells (immunogenicity), the killing of leukemic cells 
by cytotoxic immune cells, and offered explanations for leukemia dynamics observed with and 
without chemotherapy. In modeling of the impact of tyrosine kinase targeting on chronic 
myelogenous leukemia (CML) dynamics in patients, immunosuppression was formulated by the 
decrease of anti-leukemia T cell expansion rate with increasing leukemic cell concentration[16,17]. 
Recently, in modeling tumor responses and outcomes under immunotherapy combined with 
radiotherapy, targeting of PD-1, PD-L1 or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) 
as immunosuppressive mechanism in cancer progression was distinctly incorporated[18]. Our 
mathematical model incorporates leukemic cell-dependent expansion of immunosuppressive Tregs, 
which none of these models have considered as a potential target of cancer immunotherapy. 
Some modeling interactions between cancer and immune cells allowed multiple steady states and 
focused on the effectiveness of transitions between the basins of attraction by hypothetical radiation 
therapy and/or chemotherapy [19-21]. While cell-cell interactions including immunosuppressive 
mechanism in our model also give rise to two stable steady states corresponding to high and low 
concentrations of leukemic cell (L), our preliminary result was that longer CR durations observed 
in AML could be interpreted as transient dynamics in which the system spends longer time in the 
neighborhood of basin boundary before returning to the steady state with high concentration of L 
[12]. In the present study, the distribution of CR durations simulated by our model is translated to 
relapse free survival (RFS) curve which could be compared with clinical outcomes in 
immunotherapy of AML, resulting in the validation of the ability to predict the impact of 




Y. NISHIYAMA and N. NISHIYAMA               27 
2  Material and Methods 
 
The temporal evolution of the model schematized in Fig.1 is governed by a set of 3 kinetic equations 
as follows [12].  
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  We consider the populations of leukemic blast cells (L), mature regulatory T cells (Treg), and 
mature effective T cells (Teff), including CTLs and NK cells. We assume that the dynamics of each 
cell population (L, Treg, Teff) are due to constant influx and first order decay by apoptosis, in which 
constant influx rates are denoted by aL, aTreg, aTeff, and decay rate constants are denoted by dL, dTreg, 
dTeff. Three intercellular interactions were modeled as Hill functions with threshold constants (k1, k2, 
k3) specifying the strength of intercellular interactions and the Hill coefficient p [12]. 
We assume that the concentrations of drugs are constant and the decay rate of each cell population 
(L, Treg, Teff) is proportional only to the cell population ([L], [Treg], [Teff]) during hypothetical 
chemotherapy. The rate constants of decay due to apoptosis and drugs are accordingly combined 
together as dL, dTreg, dTeff during the chemotherapy. Teffs infusion and Tregs depletion as hypothetical 
immunotherapy were modeled by instantaneous increases and decreases in [Teff] and [Treg], 
respectively. 
Some parameters (aTreg, aTeff, dTreg, dTeff) in Eq. (1) were estimated using Bayesian inference via a 
Markov chain Monte Carlo (MCMC) technique (SAS v.9.4 (SAS Institute, Cary, NC)) with clinical 
data [22] of lymphocytes recovery after induction chemotherapy [12]. While keeping the parameters 
aTreg, aTeff, dTreg and dTeff to estimated values by the MCMC method, we searched a wide range of the 
parameter space of aL, dL, k1 and found parameter ranges characterized by the existence of one or 
two stable steady states separated by an unstable fixed point [12]. The values of k2, k3 and p were 
fixed to be those in parameter ranges of bistability. However, we cannot exclude the existence of 
different dynamics, such as a limit cycle. The values of model parameters in the present study are 
listed in Table 1. 
  Steady states of the model were determined as the intersection of three nullclines (d[L]/dt = 0, 
d[Teff]/dt = 0 and d[Treg]/dt = 0), which were numerically solved using the nleqslv R-package [23]. 
The ordinary differential equations in Eq.(1) were numerically solved by ode23 using second and 
third order Runge-Kutta-Fehlberg formulas with automatic step-size from MATLAB (Ver. 7.13; The 
Mathworks, Inc.).  
 
3  Results 
 
Very recently, we showed that our proposed model offers bistable steady states (denoted as SShi and 
SSlo) with low and high concentration of leukemic blast cell (L), which could be respectively 
interpreted as long-term CR and relapsed disease state [12]. The locations of two stable steady states 
in three dimensional space defined by the concentrations of L, Teff and Treg are [L]=100000/μL, 
[Teff] =0.00031/μL, [Treg]=4955/μL for SShi and [L]=40/μL, [Teff]=283/μL, [Treg]=8/μL for SSlo.  
  We assume that [L] is approximately to be a constant [L]ss during complete remission (CR) after 
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intensive induction chemotherapy. While < 5% as the percentage of leukemic blast cells present 
within the total of nucleated cells in bone marrow is given as a clinical criteria for CR in AML, there 
is no definitive criteria of peripheral circulating blasts count during CR.  According to the clinical 
observation that 0% to 5% peripheral blast cells during CR had no effects on relapse free survival 
(RFS) time[24], we could set 500/μL as [L]ss during CR with 5% peripheral blast cells and 10000/μL  
as normal counts of peripheral nucleated cells. Together, we had the definition of CR duration as the 
time interval with less than 500/μL of [L].  In addition, our interpretation of SSlo as long-term CR 
was rationalized by the definition of CR duration as [L]=40/μL of SSlo is less than the threshold 
[L]= 500/μL. SShi of [L]=100000/μL is also consistent with cell counts of peripheral leukemic blast 
in relapsed patients with AML[25]. 
 
              
 
Figure 1. Mechanistic model for crosstalk among leukemic cells and immune cells in AML. The 
processes of cell-cell interaction are numbered as follows: 1. Leukemic blast cells targeted by effector  
T cells, 2. Effector T cell suppression mediated by Treg, and 3. Treg formation promoted by leukemic 




                     Table 1: Parameter values used in the simulation 
 
                      Symbol           Value  
cell influx  
                    aL   0.1 - 1000 μL-1day-1  
                       aTeff    56.53 μL-1day-1   
                       aTreg    198.2 μL-1day-1   
cell decay 
dL    0.0001 - 1.0 day-1 
                       dTeff    0.2 day-1  
            dTreg    0.04 day-1   
                    cell interaction 
                       k1    1 - 1000 μL-1 
k2    160 μL-1  
                       k3    200 μL-1  
                       hill coefficient 
                       p    1 - 10  
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Fig.2 shows time-courses of concentrations of L, Teff and Treg in the case of hypothetical 
chemotherapy applied to the stable steady state (SShi) with high L load. With the definition of CR 
duration, it is found in Fig.2 that the system returns to the original steady state (SShi) with transient 
increase of Teff concentration during CR. CR duration depends on the arrived location in the phase 
plane of [L], [Teff] and [Treg] by hypothetical chemotherapies[12]. It also depends on the arrived 
location whether the system is forced to go to SSlo or return to SShi[12]. 
 
   
  
Figure 2. Time courses of [L], [Teff] and [Treg] after chemotherapy applied for the system staying 
at SShi. Solid lines are for [L] (blue) and [Treg] (red) and dots are for [Teff]. Parameter values are  
aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, p=4. The   
chemotherapy was applied with enhanced cell decay rate constants (dL =1.0, dTeff =0.68, dTreg =5.0) 
during 30 days. The system goes towards the original SShi after the chemotherapy with transient 
increase of [Teff]. 
 
 
 We performed Monte Carlo simulation of the trajectories from the stable steady state (SShi) with 
high L load after hypothetical chemotherapy applied with random sampling from normal 
distributions of three rate constants of cell decay (dL, dTeff, dTreg). The distributions of resulting CR 
durations were translated into relapse free survival (RFS) curves as shown in Fig.3. Fig.3 shows 
one example of RFS curves in the cases of instantaneous Teffs infusion with/without preceding 
Tregs depletion. This result suggests that infusion of Teffs such as NK cells and CTLs accompanying 
with conventional chemotherapy is effective for outcome improvement. The assumption of normal 
distributions for the rate constants was originated from patient-to-patient variability of sensitivity 
for chemotherapy. The effectiveness of Teffs infusion with/without preceding Tregs depletion was 
confirmed with normal distributions for dL, dTeff, dTreg with a wide range of standard deviations. In 
Fig.3, it is found that the three curves converge to steady ratios of RFS, which correspond to the 
ratios of the trajectories from SShi to SSlo without relapse, compared with the trajectories returning 
to the original steady state SShi. We repeated 10 times of generating RFS curves corresponding to 
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Figure 3. Relapse free survival (RFS) curves in the cases of Teffs infusion with/without Tregs depletion  
and no treatment after chemotherapy. The relapse was defined as the event that the system overrides the 
threshold of [L] towards SShi from CR states, and the duration of CR as a time interval from the   
termination of chemotherapy to the crossing of the threshold. The threshold was set to be [L]=500/μL.  
500 trajectories from SShi by applying chemotherapy during 30 days were calculated with dL, dTeff, dTreg 
of the values selected randomly from normal distributions of N(1.0,0.33), N(0.75,0.25), N(5.0,1.67),  
respectively. Instantaneous Teffs infusion or Tregs depletion was applied after 0.0001 days from time  
point of chemotherapy termination. The instantaneous Tregs depletion was followed by instantaneous  
Teffs infusion with a time interval of 0.0002 days. Increment of [Teff] by instantaneous infusion was set 
to be 200/μL and decrement of [Treg] by instantaneous depletion was set to be 100/μL. Parameter values 
are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, p=4. The 
number of the trajectories without occurring relapse was plotted against the CR duration of the last 
trajectory with relapse. 
 
those shown in Fig.3. The resulting RFS ratios at 700 days after the termination of chemotherapy 
were 35.6±2.2%, 54.8±2.7% and 54.8±2.6% for no treatment, Teffs infusion, and Teffs infusion 
with preceding Tregs depletion, respectively. Fig.4 shows the impacts of hypothetical chemotherapy 
only and Teffs infusion with preceding Tregs depletion after chemotherapy with random sampling 
from normal distributions of three cell decay rates. The incoming trajectories from SShi are divided 
into those converging to SShi and to SSlo. More trajectories converging to SSlo in the case of Teffs 
infusion with preceding Tregs depletion are observed, which are compared with the case of 
chemotherapy only and are consistent with higher ratios of RFS in the cases of Teffs infusion 
with/without preceding Tregs depletion, as shown in Fig.3. In our modeling, the effect of treatments 
of chemotherapy combined with/without Teffs infusion with/without preceding Tregs depletion 
depends on whether the system overrides the basin boundary and is forced to enter the basin of  
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Figure 4. 10 trajectories from SShi (out of figure) by applying chemotherapy only (upper figure) and 
chemotherapy followed by instantaneous Teffs infusion with preceding Tregs depletion (lower figure). 
10 trajectories from SShi by applying chemotherapy during 30 days were calculated with dL, dTeff, dTreg 
of the values selected randomly from normal distributions of N(1.0,0.33), N(0.75,0.25), N(5.0,1.67), 
respectively. Instantaneous Tregs depletion was applied after 0.0001 days from time point of 
chemotherapy termination. The instantaneous Tregs depletion was followed by instantaneous Teffs 
infusion with time interval of 0.0002 days. Increment of [Teff] by instantaneous infusion was set to be 
200/μL and decrement of [Treg] by instantaneous depletion was set to be 5/μL. Parameter values are 
aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, p=4. 
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attraction of SSlo from one of SShi. The basin boundary is shown in Fig.5, in which one trajectory 
from SShi intersects the basin boundary and converges to SSlo, while another trajectory stays in the 
basin of attraction of SShi and returns to SShi. The existence of the basin boundary suggests that 
infusion of higher number of Teff cells could be associated with treatment efficiency. While the 
impact of infused cell number may be crucial for treatments of cell transplantation, some works has 
been devoted to clarify the role of multiple cell infusions, which could avoid graft-versus-host 
disease (GVHD) with reduced number of infused cells [26]. As our modeling directs to future design 
of protocols of combined immunotherapy with chemotherapy in AML, the effectiveness of 
consecutive cycles of instantaneous Teffs infusion with/without preceding Tregs depletion as 
hypothetical immunotherapies was examined. Fig.6 shows time schedule of induction chemotherapy 
followed by consecutive cycles of instantaneous Teffs infusion with preceding Tregs depletion. The 
first Tregs depletion was applied with a time interval (duration 0) after induction chemotherapy. 
Time intervals between Tregs depletion and Teffs infusion were set to be constant (duration 1). Time 
intervals between two Teffs infusions in the case of Teffs infusion without Tregs depletion were 
double time of duration 1. Fig.7 shows one example of RFS curves for 5 cycles of Teffs infusion 
without Treg depletion and Teffs infusion with preceding Tregs depletion, compared with the case 
of no treatments. Fig.8 shows dependence of relapse free survival (RFS) rate on the number of 
consecutive cycles of instantaneous Teffs infusion with/without preceding Tregs depletion, 
compared with the case of no treatment. We repeated 10 times of generating RFS curves 
corresponding to those shown in Fig.7. The resulting RFS ratios at 700 days after the termination of 
chemotherapy were 36.5±2.7%, 54.1±1.8% and 56.7±2.1% respectively for no treatment, 5 cycles 
of Teffs infusion, and 5 cycles of Teffs infusion with preceding Tregs depletion, as shown in Fig.8. 
It should be noted that increment of [Teff] by each instantaneous infusion was set to be 40/μL and 
decrement of [Treg] by each instantaneous depletion was set to be 20/μL in Fig.7 and 8, compared 
with increment of [Teff] (200/μL) and decrement of [Treg](100/μL) in the case of Fig.3. Fig.9 shows 
examples in the cases of 3 cycles and 5 cycles of Teffs infusion with preceding Tregs depletion, 
suggesting effectiveness of more cycles of the treatment. These results shown in Fig.7, 8 and 9 
suggest the effectiveness of consecutive cycles of immunotherapy with less doses of Teffs infusion 
and Tregs depletion. 
 
           
 
Figure 5. The basin boundary denoted by a dotted plane and two trajectories from SShi (out of figure). 
Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, 
k3=200, p=4. Two trajectories from SShi by applying chemotherapy during (a) 10 days and (b) 30 days 
were calculated with the values of (a) dL=1.0, dTeff=0.75, dTreg=5.0 and (b) dL=1.0, dTeff=0.6, dTreg=5.0. 
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Figure 6. Time schedule of induction chemotherapy followed by consecutive cycles of instantaneous 
Teffs infusion with preceding Tregs depletion. The first Tregs depletion was applied with a time interval 
(duration 0) after induction chemotherapy. Time intervals between Tregs depletion and Teffs infusion 
were set to be constant (duration 1). Arrows denote time points of instantaneous Teffs infusion and 
closed circles denote time points of instantaneous Tregs depletion. 
 
         
Figure 7. Relapse free survival (RFS) curves in the cases of 5 consecutive cycles of Teff cells infusion 
with/without Treg cells depletion and no treatment after chemotherapy. The threshold for relapse was 
set to be [L]=500/μL. 500 trajectories from SShi by applying chemotherapy during 30 days were 
calculated with dL, dTeff, dTreg of the values selected randomly from normal distributions of N(1.0,0.33), 
N(0.75,0.25), N(5.0,1.67), respectively. Instantaneous Teffs infusion or Tregs depletion was applied 
after 0.0001 days from time points of chemotherapy termination. The instantaneous Tregs depletion was 
followed by instantaneous Teffs infusion with time interval of 0.0002 days. Increment of [Teff] by each 
instantaneous infusion was set to be 40/μL and decrement of [Treg] by each instantaneous depletion was 
set to be 20/μL. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, 
k1=40, k2=160, k3=200, p=4. The number of the trajectories without occurring relapse was plotted against 
the CR duration of the last trajectory with relapse. 
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Figure 8. Dependence of relapse free survival (RFS) rate on the number of consecutive cycles of 
instantaneous Teffs infusion or instantaneous Tregs depletion followed by instantaneous Teffs infusion. 
The RFS rates after 700 days from the time point of chemotherapy termination are indicated. The RFS 
rates were based on RFS curves which were estimated from 500 trajectories. Standard deviations in the 
figure were estimated from 10 RES curves. 500 trajectories from SShigh by applying chemotherapy 
during 30 days were calculated with dL, dTeff, dTreg of the values selected randomly from normal 
distributions of N(1.0,0.33), N(0.75,0.25), N(5.0,1.67), respectively. Instantaneous Teffs infusion or 
Tregs depletion was applied after 0.0001 days from the time point of chemotherapy termination. The 
instantaneous Tregs depletion was followed by instantaneous Teffs infusion with time interval of 0.0002 
days. Increment of [Teff] by each instantaneous infusion was set to be 40/μL and decrement of [Treg] 
by each instantaneous depletion was set to be 20/μL. Parameter values are aL=1000, aTeff=56.53, 
aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, k1=40, k2=160, k3=200, p=4. 
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Figure 9.  The trajectories from SShi (not shown in figure) after chemotherapy followed by consecutive 
cycles of instantaneous Teffs infusion with preceding Tregs depletion: (upper figure) 3 cycles, (lower 
figure) 5 cycles. Parameter values are aL=1000, aTeff=56.53, aTreg=198.2, dL=0.01, dTeff=0.2, dTreg=0.04, 
k1=40, k2=160, k3=200, p=4. Chemotherapy during 30 days were applied with dL=1.0, dTeff=0.69, 
dTreg=5.0. First instantaneous Tregs depletion was applied after 0.0001 days from the time point of 
chemotherapy termination. The instantaneous Tregs depletions were followed by instantaneous Teff 
infusions with the time interval of 0.0002 days. Increment of [Teff] by each instantaneous infusion was 
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4  Discussion 
 
Our model proposed recently was capable of explaining variable CR durations as clinical finding[12]. 
Especially, long-term CR duration was suggested to associate with transient dynamics in the 
neighborhood of basin boundary [12]. In the present study, we translated the distributions of 
simulated CR durations into RFS curves which could be compared with clinical data. Curti et al.[27] 
suggested the effectiveness of allogeneic NK cell infusion as post CR consolidation treatment for 
elderly AML patients and identified higher number of infused NK cells as a favorable prognostic 
factor. They reported improved outcomes for patients in CR receiving NK cells infusion(n=16, RFS 
ratio=0.56 with a median follow-up of 22.5 months), compared with non-NK cells-treated 
control(n=15, RFS ratio=0.25). Bachanova et al. focused on the impact of preceding Tregs depletion 
followed by NK cells infusion, with the hypothesis that Tregs may suppress the effectiveness of anti-
leukemic NK cell infusion[10]. Patients with refractory AML received Tregs depletion with IL-2 
diphtheria toxin (IL2DT), which could selectively deplete IL-2 receptor expressing cells, including 
Tregs. They reported that RFS ratio is 33% (n=42) at 6 month after NK cells infusion with adding 
IL2DT, compared with 5% for patients (n=15) receiving only NK cells infusion[10]. With our 
present model, RFS curves were produced numerically by assuming that cell decay rate constants 
of L, Teff and Treg characterizing hypothetical chemotherapy are random variables with normal 
distributions. Despite such simplifications, the model was qualitatively capable to explain the 
effectiveness of a single infusion of NK cells compared with only chemotherapy, as shown in Fig.3. 
In general, consecutive cycles of cell infusion with minimal cell number have been used in 
immunotherapy, as a single infusion of high number of Teff cells is often associated with higher 
incidence of GVHD. Dazzi et al. examined the effectiveness of consecutive cycles of donor 
lymphocyte infusion with lower cell number for relapsed patients with chronic myeloid 
leukemia[26]. They suggested that the occurrence of GVHD in patients is significantly inhibited 
with consecutive cycles of cell infusion, compared with that in the case of a single administration of 
comparable total cell number, while the difference of remission achievement between the two groups 
is not significant. In general, the protocols of NK cells infusion for AML are in line with this study, 
in which a single infusion of NK cells is followed by consecutive cycles of IL2 administration for 
infused NK cell activation[10,27]. Although there are no clinical studies which could directly 
evaluate our results of the impact of consecutive cycles of instantaneous Teffs infusion with/without 
preceding Tregs depletion as shown in Fig.8, the effectiveness of consecutive activation of 
endogenous T cells and NK cells for AML [28-30] supports the ability of our modeling to predict 
the outcomes. Brune et al. [28] reported that consecutive administration of IL2 and histamine 
dihydrochloride (HDC) for patients with AML in CR significantly improved RFS, compared with 
patients with no treatment, which is comparable with our results shown in Fig.8. 
 
5  Conclusion 
 
Our model might be proposed to be a candidate to contribute to make determination of optimal 
dosing and scheduling of immune cell modulation for AML, while the location of the boundary of 
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